Hepatocyte growth factor prevents peritoneal fibrosis in an animal model of encapsulating peritoneal sclerosis.

Background: Ultrafiltration failure associated with peritoneal fibrosis can lead patients to discontinue continuous ambulatory peritoneal dialysis (CAPD). It has been reported that the reciprocal imbalance between transforming growth factor-beta1 (TGF-beta1) and hepatocyte growth factor (HGF) is closely involved in the progression of tissue fibrosis. We previously showed that exogenous HGF restores the growth of human peritoneal mesothelial cells suppressed by a high concentration of D-glucose or TGF-beta1.

Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis.

Objective: Some patients who had carried out long-term continuous ambulatory peritoneal dialysis discontinued the treatment because of progressive peritoneal fibrosis. It has been previously reported that transforming growth factor-beta1 (TGF-beta1) is one of the factors that induces peritoneal fibrosis. Also, hepatocyte growth factor (HGF) plays a role in the prevention of fibrosis and in inhibiting TGF-beta1 production.

Osseointegration under immediate loading: biomechanical stress-strain and bone formation--resorption.

During the past 10 years, clinicians have used two-piece implants as a one-piece system for immediate loading to accomplish early recovery for function and esthetics. The statistical analysis by the Institute of Clinical Materials demonstrates high survival rates of 92.3 +/- 8.